Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_2899_Библиотеки_им_академика_М_И_Перельмана
.pdf
IfsuspectedparoxysmalAFwithmultipleepisodesin24hours,consideranambulatory
ECG monitor (‘Holter’). If episodes are >24 hours apart, consider using a longer
ambulatoryECGorotherECGtechnology(includinganimplantablelooprecorder).
Management
Acutemanagement
Aim to correct any reversible causes of recent-onset AF, such as infection and
hypovolaemia,andconsidertheneedforanticoagulation(Box4.2).Anoverviewofacute
managementiscoveredinFig.4.2.
Fig.4.2Theacutemanagementofatrialfibrillation.
Box4.2Anticoagulationintheacutephase
https://t.me/med1917

•
•
Do not delay emergency electrical cardioversion solely for achieving anticoagulation if
haemodynamicallyunstable
Givelow-molecular-weightheparin(LMWH)untilfullriskassessmentcanbecarriedout.
Haemodynamicallyunstable
Urgentcardioversionisrequired(seeChapter123).
Haemodynamicallystable
Acuteratecontrol
There is no clear evidence of an optimal target ventricular rate. A resting heart rate of
<110bpmisacceptable.SeeFig.4.3,Box4.3,andTable4.1.
https://t.me/med1917

Fig. 4.3 Choice of rate control therapy. BB, beta-blocker; CCB, calcium channel blocker; HF, heart
failure.
Box4.3Whichratecontroltherapytochoose?
https://t.me/med1917

•
•
•
•
•
•
•
•
Beta-blockersorcalciumchannelblockersarefirstline
Calcium channel blockers are contraindicated in pulmonary oedema or when left ventricular
ejectionfractionis<40%
Digoxinmayalsobeusedfirstlineifthepatient issedentaryand/orabeta-blockerorcalcium
channelblockercannotbegiven
Anytwo ofbeta-blocker,diltiazem, anddigoxinmay be usedincombinationifratecontrolis
inadequatewithasingleagent.Specialistadviceisneededasthismaycausebradycardia.
DrugdosesarelistedinTable4.1.
Source:datafromNICECG180.
Table4.1Drugdosesforratecontrolinatrialfibrillation
Drug Oraldose IVdose(boluses)
Bisoprolol 1.25–10mgdaily
Metoprolol 2.5–10mg
Diltiazem(standardrelease) 120mgdaily(unlicensed)
Verapamil(standardrelease) Upto120mgTDS 2.5–10mg
Digoxin 62.5–250mcg 500mcg(max.1.5mg/24hours)
Acuterhythmcontrol
If a rate control strategy has not worked, or if symptoms persist despite the heart rate
beingbroughtdown,rhythmcontrolshouldbeconsidered.
Thismaybeachievedusingelectricalorpharmacologicalcardioversion.
A rhythm control strategy is also more preferablethan rate control for thefollowing
patientgroups:
AFwithreversiblecause
HeartfailurecausedbyAF
New-onsetAF(within48hours).
Electricalcardioversion
This requires short-acting general anaesthesia or conscious sedation with anaesthetic
support.
It may be used in conjunction with antiarrhythmic therapy (e.g. amiodarone) to
increasethechanceofsuccessandlowertheenergyrequirement.
If elective cardioversion is planned for AF which has been present for >48 hours,
anticoagulationshouldbegivenfor3weeksuntilcardioversiontakesplace,andthenthe
needforlong-termanticoagulationshouldbeassessed(see‘Long-termanticoagulation’).
https://t.me/med1917

Anticoagulationmaynotbenecessaryinthissettingifatransoesophagealechocardiogram
hasexcludedthepossibilityofaclotintheleftatriumorleftatrialappendage.
Pharmacologicalcardioversion
Flecainide can be given in an acute setting or may be self-administered by the patient
(‘pillinthepocket’)asasinglebolus(oral,100–150mg)inanoutpatientsetting.
Thisiscontraindicatedinpatientswithstructural,valvular,orischaemicheartdisease.
Amiodaroneisanalternativechoicein thesepatients(IV, 5mg/kgover 20–120minutes,
maximum1.2g/24hours).
Treatmentafterstabilization
Long-termrhythmcontrol
If onset of AF was >48 hours ago, electrical cardioversion can be considered after a
period of at least 3 weeks of anticoagulation. To increase the success rate of electrical
cardioversion,theuseofamiodaronefor4weeksbeforeandupto12monthsaftercan
beconsidered.
Long-termratecontrol
Drug choices are similar to those used in acute rate control (Table 4.1). Combination
therapyisoftenrequiredtoachieveadequatecontrol.Amiodaroneisnotnormallyoffered
aslong-termratecontrol.
Long-termanticoagulation
The decision should be guided by clinical risk scores (Table4.2) and reviewed at least
annually.
https://t.me/med1917

Table4.2Strokeversusbleedingrisks
CHA2DS2-VAScstrokeriskscore ORBITbleedingriskscore
Congestiveheartfailure=1
Hypertension(treatedoruntreated)=1
Age≥75=2
Diabetesmellitus=1
StrokeorTIA=2
Vascular(myocardialinfarction,peripheralarterialdisease,aortic
plaque)=1
Age65–74=1
Sex,female=1
Anaemia(<13mg/dLinmen,<12mg/dLin
women)=2
Age>74=1
Bleedinghistory=2
GFR<60mL/min/1.73m2=1
Treatmentwithantiplateletagents=1
CHA2DS2-VAScscore:consideranticoagulationifscore≥1inmenandoffertomenandwomenif≥2
ORBITscore:≤2=lowbleedingrisk;3=mediumbleedingrisk;4–7=highbleedingrisk
AdaptedfromLipGYH,NieuwlaatR,PistersR,LaneDA,CrijnsHJGM.Refiningclinicalrisk
stratificationforpredictingstrokeandthromboembolisminatrialfibrillationusinganovelriskfactorbasedapproach:theEuroHeartSurveyonatrialfibrillation.Chest.2010Feb;137(2):263–72and
O’BrienEC,SimonDN,ThomasLE,HylekEM,GershBJ,AnsellJE,KoweyPR,MahaffeyKW,Chang
P,FonarowGC,PencinaMJ,PicciniJP,PetersonED.TheORBITbleedingscore:asimplebedside
scoretoassessbleedingriskinatrialfibrillation.EurHeartJ.2015Dec7;36(46):3258–64.
If anticoagulation is recommended, offer a direct oral anticoagulant (DOAC)
(rivaroxaban,apixaban,dabigatran,edoxaban)firstline.Ifcontraindicated,nottolerated,
orunsuitable,offerwarfarin.
Ifanticoagulationisnotappropriate,leftatrialappendageocclusioncanbeconsidered.
Patientswhoaretakinglong-termanticoagulationshouldbemonitoredandsupported
toimproveanyotherriskfactorsforbleedingincludinguncontrolledhypertension,labile
international normalized ratio (INR), interacting medications, excessive alcohol intake,
andreversiblecausesofanaemia.
Ifthepatientisatriskoffallingorelderly,thesereasonsalonearenotajustificationfor
withholdinganticoagulation.
Specialconsiderations
Ablation
Ablation is considered when medical treatment has failed, is not appropriate, or
concomitant heart failure is present. This can take the form of atrioventricular node
ablation,leftatrialcatheterorsurgicalablation.
https://t.me/med1917

Long-term anticoagulation should be considered if there is a risk of recurrence (see
‘Long-termanticoagulation’).
Postoperativeatrialfibrillation
Rhythmcontrolispreferredoverratecontrolfollowingcardiothoracicsurgery.
Furtherreading
1. Kirchhof P, Benussi S, Kotecha D, et al. (2016). ESC Guidelines for the management of atrial
fibrillationdevelopedincollaborationwithEACTS.EurHeartJ.37:2893–962.
2. Scottish Intercollegiate Guidelines Network (2014). Prevention of stroke in patients with atrial
fibrillation.Availableat:https://www.sign.ac.uk/assets/af_publication.pdf
3. Royal College of Emergency Medicine Learning (2019). Atrial fibrillation. Available at:
https://www.rcemlearning.co.uk/reference/atrial-fibrillation/
https://t.me/med1917

Chapter5
Chronicheartfailure
Guideline: NICE NG106 (Chronic heart failure in adults: diagnosis and
management):https://www.nice.org.uk/guidance/ng106
OUPdisclaimer:OxfordUniversity Press makesno representation, express
or implied, that the drugdosagesarecorrectand thatthe recommendations
are an exclusive or mandatory course of care. All health professionals
readingthistexthavearesponsibilitytoevaluateitsappropriatenessandtake
theindividualneedsofthepatientintoaccount.
Localtrustguidelines:pleaserefertoyourlocalguidelinesasnecessary.
Overview
The population of patients who suffer from chronic heart failure (CHF) is increasing.
CHF may bedivided into left- and right-sided failure. Left-sided failure often develops
duetocoronaryheartdiseaseand,asitworsens,canleadtoright-sidedfailure.CHFmay
alsobedividedintoheartfailurewithreducedejectionfraction(HFrEF)(ejectionfraction
<40%) and heart failure with preserved ejection fraction (HFpEF) (ejection fraction
≥40%).
Diagnosis
History
Symptoms include dyspnoea, orthopnoea, paroxysmal nocturnal dyspnoea, ankle
swelling, andreduced exercisetolerance. Lesscommonly,patientsmayreportnocturnal
cough,wheezing,andweightgain.
TheNewYorkHeartAssociation(NYHA)classification dividesCHFintofour classes
basedonsymptomsandfunctionallimitation(Table5.1).
https://t.me/med1917

•
•
•
•
•
•
•
•
•
•
•
•
Table5.1TheNYHAfunctionalclassificationsystem
Class Description
I Nolimitation
II Slightlimitation
III Markedlimitation
IV Symptomspresentatrest
Source:DolginM,NewYorkHeartAssociationNYH,FoxAC,GorlinR,LevinRI,NewYorkHeart
Association.CriteriaCommittee.Nomenclatureandcriteriafordiagnosisofdiseasesoftheheartand
greatvessels.9thed.Boston,MA:LippincottWilliamsandWilkins;March1,1994.
Examination
Generalsigns:cachexia,tachypnoea
Necksigns:elevatedJVP,hepatojugularreflux
Cardiacsigns:laterallydisplacedapexbeat,S3,S4,galloprhythm,pansystolicmurmur
Respiratory signs: bilateral coarse crepitations, pleural effusion (dull percussion, reduced air
entry)
Abdominalsigns:hepatomegaly,ascites
Peripheralsigns:peripheraloedema(ankle,sacral).
Investigations
Bedside
Electrocardiography(ECG)
ItisunusualtohaveCHFwithanormalECG.Pathologicalchangesmayinclude:
PathologicalQwaves(previousinfarction)
LBBB
AF
Non-specificST/Twavechanges.
Considerforevaluationofriskfactors
Urinalysis:mayshowglycosuria(diabetes)orproteinuria(renaldisease)
Peakflow:COPD.
Bloods
https://t.me/med1917

•
•
•
•
•
•
•
•
•
•
•
•
•
•
FBC
U&E(inanticipationofdiuretictherapy)
LFT(maybeabnormalinright-sidedheartfailureormayindicateexcessivealcoholintakewhich
canleadtoCHF)
TFT(thyrotoxicosisandhypothyroidismareriskfactorsforCHF)
HbA1c(diabetesisariskfactorforCHF)
NT-proBNPorBNP(Box5.1).
Box5.1NT-proBNPandBNP
The heart produces the hormones NT-proBNP and BNP when the ventricles are
stretched. The serum levels of NT-proBNP and BNP have a high negative predictive
valueandareprognostic.Theyareusedtostratifytheurgencyofinvestigations:
NT-proBNP<400ng/L(orBNP<100pg/mL):CHFunlikely
NT-proBNP400–2000ng/L(orBNP100–400pg/mL):TTE,specialistreviewwithin6weeks
NT-proBNP>2000ng/L(orBNP<400pg/mL):TTE,specialistreviewwithin2weeks.
Notethatlevelsmaybelowerinsomepeoplewithobesity orAfrican/African-Caribbeanheritageor
whoaretakingdrugssuchasACEinhibitors.Theymaybehigherinpatientsaged>70years,orthose
withconditionssuchasCOPD,renaldisease,ordiabetes.
Imaging
TTE should be performed in patients with raised NT-proBNP or an abnormal ECG to
assess:
Valvularfunction
Systolicanddiastolicventricularfunction
Intracardiacshunts(atrialorventricularseptaldefects,orpatentforamenovale)
Pulmonaryarterysystolicpressure(suggestiveofright-sidedheartfailureifraised)
Wallmotionabnormalities(evidenceofapreviouscardiacevent).
Cardiac MRI, transoesophageal echocardiography, or radionuclide angiography can be
consideredifTTEimagesarepoor.
Chest X-ray is recommended to exclude other causes of dyspnoea. There may be
evidenceof cardiomegalyandother signswhich aretypicallyseen in acuteheartfailure
(seeChapter2).
Management
Lifestyleandsimpleinterventions
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана
